Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $41.83

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $41.8333.

STOK has been the topic of several research analyst reports. HC Wainwright boosted their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Wolfe Research started coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective on the stock. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Chardan Capital reissued a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Finally, Loop Capital set a $35.00 price target on Stoke Therapeutics in a research report on Monday, January 5th.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $32.74 on Wednesday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $40.22. The firm has a market cap of $1.94 billion, a P/E ratio of -272.81 and a beta of 1.22. The business’s 50 day moving average price is $33.26 and its 200-day moving average price is $30.79.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.97) EPS for the quarter. The business had revenue of $1.40 million during the quarter. Stoke Therapeutics had a negative return on equity of 2.05% and a negative net margin of 3.73%. As a group, equities analysts predict that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, CFO Thomas Leggett sold 2,382 shares of the business’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $74,651.88. Following the sale, the chief financial officer owned 10,172 shares in the company, valued at approximately $318,790.48. The trade was a 18.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Barry Ticho sold 6,686 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $209,539.24. Following the completion of the sale, the insider directly owned 40,798 shares in the company, valued at $1,278,609.32. This represents a 14.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 69,699 shares of company stock valued at $2,526,714. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. purchased a new stake in shares of Stoke Therapeutics in the 3rd quarter worth approximately $1,062,000. Marshall Wace LLP boosted its holdings in Stoke Therapeutics by 7.9% in the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after acquiring an additional 168,771 shares in the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Stoke Therapeutics in the third quarter worth $3,539,000. Franklin Resources Inc. grew its stake in shares of Stoke Therapeutics by 264.8% in the second quarter. Franklin Resources Inc. now owns 81,395 shares of the company’s stock worth $924,000 after acquiring an additional 59,081 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Stoke Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after acquiring an additional 217,616 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.